Literature DB >> 29209638

Sensitizing HR-proficient cancers to PARP inhibitors.

Elgene Lim1,2, Shawn F Johnson2, Matthias Geyer3,4, Violeta Serra5,6, Geoffrey I Shapiro2,7.   

Abstract

Entities:  

Keywords:  CDK12 inhibitors; PARP inhibitors; Triple negative breast cancer

Year:  2017        PMID： 29209638      PMCID： PMC5706951          DOI： 10.1080/23723556.2017.1299272

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


× No keyword cloud information.
  10 in total

1.  Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing.

Authors:  Kaiwei Liang; Xin Gao; Joshua M Gilmore; Laurence Florens; Michael P Washburn; Edwin Smith; Ali Shilatifard
Journal:  Mol Cell Biol       Date:  2015-01-05       Impact factor: 4.272

2.  CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.

Authors:  Shawn F Johnson; Cristina Cruz; Ann Katrin Greifenberg; Sofia Dust; Daniel G Stover; David Chi; Benjamin Primack; Shiliang Cao; Andrea J Bernhardy; Rhiannon Coulson; Jean-Bernard Lazaro; Bose Kochupurakkal; Heather Sun; Christine Unitt; Lisa A Moreau; Kristopher A Sarosiek; Maurizio Scaltriti; Dejan Juric; José Baselga; Andrea L Richardson; Scott J Rodig; Alan D D'Andrea; Judith Balmaña; Neil Johnson; Matthias Geyer; Violeta Serra; Elgene Lim; Geoffrey I Shapiro
Journal:  Cell Rep       Date:  2016-11-22       Impact factor: 9.423

Review 3.  Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.

Authors:  Clare L Scott; Elizabeth M Swisher; Scott H Kaufmann
Journal:  J Clin Oncol       Date:  2015-03-16       Impact factor: 44.544

4.  Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.

Authors:  David Parry; Timothy Guzi; Frances Shanahan; Nicole Davis; Deepa Prabhavalkar; Derek Wiswell; Wolfgang Seghezzi; Kamil Paruch; Michael P Dwyer; Ronald Doll; Amin Nomeir; William Windsor; Thierry Fischmann; Yaolin Wang; Martin Oft; Taiying Chen; Paul Kirschmeier; Emma M Lees
Journal:  Mol Cancer Ther       Date:  2010-07-27       Impact factor: 6.261

5.  Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors.

Authors:  Poorval M Joshi; Shari L Sutor; Catherine J Huntoon; Larry M Karnitz
Journal:  J Biol Chem       Date:  2014-02-19       Impact factor: 5.157

6.  BRCA1 pathway function in basal-like breast cancer cells.

Authors:  Sarah J Hill; Allison P Clark; Daniel P Silver; David M Livingston
Journal:  Mol Cell Biol       Date:  2014-08-04       Impact factor: 4.272

7.  Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.

Authors:  Tari A King; Weiwei Li; Edi Brogi; Cindy J Yee; Mary L Gemignani; Narciso Olvera; Douglas A Levine; Larry Norton; Mark E Robson; Kenneth Offit; Patrick I Borgen; Jeff Boyd
Journal:  Ann Surg Oncol       Date:  2007-06-29       Impact factor: 5.344

Review 8.  Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?

Authors:  Peter Bouwman; Jos Jonkers
Journal:  Clin Cancer Res       Date:  2013-11-22       Impact factor: 12.531

9.  The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes.

Authors:  Dalibor Blazek; Jiri Kohoutek; Koen Bartholomeeusen; Eric Johansen; Petra Hulinkova; Zeping Luo; Peter Cimermancic; Jernej Ule; B Matija Peterlin
Journal:  Genes Dev       Date:  2011-10-15       Impact factor: 11.361

10.  53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers.

Authors:  Peter Bouwman; Amal Aly; Jose M Escandell; Mark Pieterse; Jirina Bartkova; Hanneke van der Gulden; Sanne Hiddingh; Maria Thanasoula; Atul Kulkarni; Qifeng Yang; Bruce G Haffty; Johanna Tommiska; Carl Blomqvist; Ronny Drapkin; David J Adams; Heli Nevanlinna; Jiri Bartek; Madalena Tarsounas; Shridar Ganesan; Jos Jonkers
Journal:  Nat Struct Mol Biol       Date:  2010-05-09       Impact factor: 15.369
  10 in total
  4 in total

Review 1.  Response prediction biomarkers and drug combinations of PARP inhibitors in prostate cancer.

Authors:  Yi-Xin Chen; Li-Ming Tan; Jian-Ping Gong; Ma-Sha Huang; Ji-Ye Yin; Wei Zhang; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  Acta Pharmacol Sin       Date:  2021-02-15       Impact factor: 6.150

Review 2.  Exploiting replicative stress in gynecological cancers as a therapeutic strategy.

Authors:  Natalie Yl Ngoi; Vignesh Sundararajan; David Sp Tan
Journal:  Int J Gynecol Cancer       Date:  2020-06-22       Impact factor: 3.437

Review 3.  Therapeutic Advances in Oncology.

Authors:  Jinsha Liu; Priyanka Pandya; Sepideh Afshar
Journal:  Int J Mol Sci       Date:  2021-02-18       Impact factor: 5.923

Review 4.  Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition.

Authors:  Daniel R Principe
Journal:  Cancers (Basel)       Date:  2022-02-11       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.